Non-Therapeutic Biomolecules Market, By Trade Pharma (Enzymes, Recombinant Proteins, Plasmids, Peptides, Oligonucleotides, Monoclonal Antibodies), By End User (Research, Pharma, In vitro diagnostics(IVD), Others), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Non-Therapeutic Biomolecules Market size was valued at USD 25,314.8 million in 2022, expanding at a CAGR of 12.7% from 2023 to 2030.
Non-therapeutic biomolecules refer to biomolecules that are not used for therapeutic purposes or medical treatments. Biomolecules are organic molecules found in living organisms, including proteins, carbohydrates, lipids, and nucleic acids. Non-therapeutic biomolecules play a crucial role in agriculture. Non-therapeutic biomolecules are vital in the field of biotechnology and bioengineering. They are used in the development and production of bio-based products, biofuels, bioactive compounds, and biopolymers.
Non-Therapeutic Biomolecules Market- Market Dynamics
- The rapidly increasing number of research and laboratory testing is expected to propel the growth of the non-therapeutic biomolecules market going forward.
A large number of laboratory analyses support exact diagnosis in over 50% of all diseases, in addition to serving the monitoring of drug therapy in many other cases. Laboratory medicine is therefore a vital component in the differential diagnosis in the clinic and in local general practice. The increasing focus on understanding the complex mechanisms of life and developing innovative technologies necessitates the use of non-therapeutic biomolecules. Researchers require a wide range of biomolecules to investigate biological systems, develop new methodologies, and validate hypotheses. The growth of academic and industrial research initiatives worldwide contributes to the demand for non-therapeutic biomolecules.
Non-Therapeutic Biomolecules Market- Key Insights
- As per the analysis shared by our research analyst, the global Non-Therapeutic Biomolecules market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
- The Non-Therapeutic Biomolecules industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on Trade Pharma segmentation, monoclonal antibodies were predicted to show maximum market share in the year 2022
- On the basis of region, Asia pacific was the leading revenue generator in 2022
Non-Therapeutic Biomolecules Market- Segmentation Analysis:
The Global Non-Therapeutic Biomolecules Market is segmented on the basis of Trade Pharma, Application, and Region.
The market is divided into six categories based on Trade Pharma: enzymes, Recombinant Proteins, Plasmids, Peptides, Oligonucleotides, and Monoclonal Antibodies. The monoclonal antibodies segment dominates the market. Monoclonal antibodies have revolutionized the field of therapeutics, offering precise targeting and treatment options for various diseases.
The market is divided into two categories based on application: Research, Pharma, and In vitro diagnostics (IVD) Residential. Non-therapeutic biomolecules are essential tools in research and development across various scientific disciplines. They are used to study biological processes, investigate disease mechanisms, and develop new therapeutic interventions. And also Non-therapeutic biomolecules are extensively used in the field of in vitro diagnostics (IVD). IVD refers to tests and procedures performed on biological samples outside the living organism to diagnose diseases, monitor health conditions, and guide treatment decisions.
Non-Therapeutic Biomolecules Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Asia Pacific is expected to dominate the growth of the Non-Therapeutic Biomolecules Market, due to the increasing government investments and R&D expenditure in the pharmaceutical and biochemical companies. China's total expenditure on research and development (R&D) crossed the 3-trillion-yuan mark to reach nearly 3.09 trillion yuan (USD456 billion) in 2022, up 10.4% year on year, according to the National Bureau of Statistics. In 2019, the Chinese pharmaceutical industry vigorously implements the Healthy China 2030 strategy and comprehensively promotes high-quality development. Followed by Asia, Europe, and North America expected to provide growth opportunities for Non-Therapeutic Biomolecules Market.
Non-Therapeutic Biomolecules Market- Competitive Landscape:
As research activities expand and the demand for innovative solutions and technologies rises, the non-therapeutic biomolecules market is expected to experience significant growth. Companies involved in the production, development, and supply of non-therapeutic biomolecules are likely to benefit from this increasing demand. Products makers compete on a variety of aspects, including product costs, performance, product making, technology, reputation, and availability. The market is expected to witness significant growth due to the demand for innovative solutions, sustainable products, and advancements in scientific research. For example, Merck, a leading science and technology company, has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies.
Recent Developments:
- In May 12, 2022, Bio-Techne Corporation and Nonagen Bioscience nowadays announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria bladder cancer diagnostic panel using xMAP Luminex technology.
Key features of the study:
- This proposed research study on Non-Therapeutic Biomolecules market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Non-Therapeutic Biomolecules market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Non-Therapeutic Biomolecules market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Non-Therapeutic Biomolecules market
- Impact of COVID-19 on Non-Therapeutic Biomolecules market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Non-Therapeutic Biomolecules market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Non-Therapeutic Biomolecules market, we have also included competitive landscape and key innovator analysis for the Non-Therapeutic Biomolecules market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Non-Therapeutic Biomolecules market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Non-Therapeutic Biomolecules market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NON-THERAPEUTIC BIOMOLECULES MARKET KEY PLAYERS
- Merck Group
- Bio-Synthesis Inc.
- Eurogentec
- Aviva Systems Biology
- RayBiotech
- Biocon Limited
- Bio-Techne Corporation
- Danaher Corporation
GLOBAL NON-THERAPEUTIC BIOMOLECULES MARKET, BY TRAD PHARMA
- Enzymes
- Recombinant Proteins
- Plasmids
- Peptides
- Oligonucleotides
- Monoclonal Antibodies
GLOBAL NON-THERAPEUTIC BIOMOLECULES MARKET, BY END-USER
- Research
- Pharma
- In vitro diagnostics(IVD)
- Others
GLOBAL NON-THERAPEUTIC BIOMOLECULES MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Non-Therapeutic Biomolecules Market Overview
1.1. Study Scope
2. Executive Summary
2.1. Market Snippet
2.1.1. Non-Therapeutic Biomolecules Market Snippet by Trade Pharma
2.1.2. Non-Therapeutic Biomolecules Market Snippet by End-user
2.1.3. Non-Therapeutic Biomolecules Market Snippet by Country
2.1.4. Non-Therapeutic Biomolecules Market Snippet by Region
2.2. Competitive Insights
3. Non-Therapeutic Biomolecules Key Market Trends
3.1. Non-Therapeutic Biomolecules Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Non-Therapeutic Biomolecules Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Non-Therapeutic Biomolecules Market Opportunities
3.4. Non-Therapeutic Biomolecules Market Future Trends
4. Non-Therapeutic Biomolecules Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Non-Therapeutic Biomolecules Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Non-Therapeutic Biomolecules Market Landscape
6.1. Non-Therapeutic Biomolecules Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Non-Therapeutic Biomolecules Market – By Trade Pharma
7.1. Overview
7.1.1. Segment Share Analysis, By Trade Pharma, 2022 & 2030 (%)
7.1.2. Enzymes
7.1.3. Recombinant Proteins
7.1.4. Plasmids
7.1.5. Peptides
7.1.6. Oligonucleotides
7.1.7. Monoclonal Antibodies
8. Non-Therapeutic Biomolecules Market – By End-user
8.1. Overview
8.1.1. Segment Share Analysis, By End-user, 2022 & 2030 (%)
8.1.2. Research
8.1.3. Pharma
8.1.4. In vitro diagnostics(IVD)
8.1.5. Others
9. Non-Therapeutic Biomolecules Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
9.2. North America
9.2.1. Overview
9.2.2. Non-Therapeutic Biomolecules Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.2.4. North America Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.2.5. North America Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Non-Therapeutic Biomolecules Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.5. Europe Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.7. Italy
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.7.3. Italy Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.7.4. Italy Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.8. United Kingdom
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.8.3. United Kingdom Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.8.4. United Kingdom Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.9. France
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.9.3. France Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.9.4. France Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.10. Russia
9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.10.2. Russia Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.10.3. Russia Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.11. Netherlands
9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.11.2. Netherlands Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.11.3. Netherlands Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.12. Sweden
9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.12.2. Sweden Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.12.3. Sweden Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.13. Poland
9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.13.2. Poland Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.13.3. Poland Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.3.14. Rest of Europe
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.14.3. Rest of the Europe Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.3.14.4. Rest of the Europe Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Non-Therapeutic Biomolecules Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.6. India
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.6.3. India Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.6.4. India Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.7.3. China Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.7.4. China Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.8.3. Japan Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.8.4. Japan Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.9.3. South Korea Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.9.4. South Korea Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.11. Thailand
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.11.3. Thailand Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.11.4. Thailand Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.12. Indonesia
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.12.3. Indonesia Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.12.4. Indonesia Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Non-Therapeutic Biomolecules Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.5.5. Latin America Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Non-Therapeutic Biomolecules Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.7. United Arab Emirates
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.7.3. United Arab Emirates Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.7.4. United Arab Emirates Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Trade Pharma, 2018 - 2030 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By End-user, 2018 - 2030 (US$ Million)
10. Key Vendor Analysis- Non-Therapeutic Biomolecules Industry
10.1. Competitive Dashboard
10.2. Company Profiles
10.2.1. Merck Group
10.2.2. Bio-Synthesis Inc.
10.2.3. Eurogentec
10.2.4. Aviva Systems Biology
10.2.5. RayBiotech
10.2.6. Biocon Limited
10.2.7. Bio-Techne Corporation
10.2.8. Danaher Corporation
11. 360 Degree Analyst View
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
